BIOCQ — Biocept Income Statement
0.000.00%
- $0.00m
- -$4.46m
- $25.86m
Annual income statement for Biocept, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2018 December 31st | 2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 3.25 | 5.53 | 27.5 | 61.2 | 25.9 |
Cost of Revenue | |||||
Gross Profit | -6.8 | -5.45 | 6.12 | 23.5 | -2.58 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Total Operating Expenses | 27.5 | 28.6 | 42.9 | 63.7 | 57.8 |
Operating Profit | -24.3 | -23.1 | -15.5 | -2.41 | -32 |
Total Net Non Operating Interest Income / Expense | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -24.6 | -25.1 | -17.8 | -2.7 | -32.2 |
Provision for Income Taxes | |||||
Net Income After Taxes | -24.6 | -25.1 | -17.8 | -2.82 | -32.1 |
Net Income Before Extraordinary Items | |||||
Extraordinary Items | |||||
Net Income | -24.6 | -25.1 | -17.8 | -2.82 | -32.1 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -25.2 | -25.3 | -17.8 | -2.82 | -32.1 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -2,703 | -367 | -45.1 | -5.73 | -56.8 |